<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848093</url>
  </required_header>
  <id_info>
    <org_study_id>160/08</org_study_id>
    <nct_id>NCT01848093</nct_id>
  </id_info>
  <brief_title>Mucin Concentration in Sputum From COPD Patients During a Pulmonary Exacerbation</brief_title>
  <acronym>mucinCOPDex</acronym>
  <official_title>Molekularbiologische Eigenschaften Des Sputums w√§hrend Einer Pulmonalen COPD Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      chronic obstructive pulmonary disease (COPD) is typically associated with mucus
      hypersecretion in the airways. In health, mucin is the major macromolecular component and is
      responsible for the protective and clearance properties of the mucus gel. In a recent study
      the investigators found that mucins are decreased and unstable in the sputum of adult cystic
      fibrosis (CF) patients.

      In this study the investigators want to investigate the differences on the mucin quantity and
      quality of airway secretions during pulmonary exacerbation of patients with COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that during an exacerbation the mucin amount is increasing.

      The aim of this study is to evaluate the molecular (mucins) and structure properties
      (mucin-stability) of the airway secretions in COPD related to the severity of the disease.

      We characterize sputum composition of patients with pulmonary exacerbations. Using gel
      electrophoresis, with specific antibodies we will analyze MUC5AC and MUC5B mucins.

      The significance of these studies is that they will give us novel information about the
      pathogenesis of chronic inflammatory airway diseases, provide tools for assessing the
      progression of lung disease, and most critically, will identify novel opportunities and
      targets for therapeutic intervention.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mucin concentration</measure>
    <time_frame>2 month</time_frame>
    <description>analyzing mucin concentration by western</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mucin stability</measure>
    <time_frame>2 month</time_frame>
    <description>analyzing mucin stability at 37C over 24 hours</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>COPD exacerbation</arm_group_label>
    <description>COPD Stadium 2 and 3 during pulmonary exacerbation
sputum collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sputum collection</intervention_name>
    <description>collecting of spontaneous sputum from the patient</description>
    <arm_group_label>COPD exacerbation</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      sputum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients Stadium 2-3 during pulmonary exacerbation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  forced expiratory volume at one second (FEV1) &lt; 80%

          -  sputum production

          -  clinical likely hood of exacerbation

        Exclusion Criteria:

          -  FEV1 &gt; 80% or &lt; 30%

          -  increased systemic inflammation

          -  susceptibility of pneumonia

          -  need for antibiotic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Henke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Marburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>pulmonary department, University Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions. Am J Respir Cell Mol Biol. 2004 Jul;31(1):86-91. Epub 2004 Feb 26.</citation>
    <PMID>14988081</PMID>
  </reference>
  <reference>
    <citation>Henke MO, John G, Rheineck C, Chillappagari S, Naehrlich L, Rubin BK. Serine proteases degrade airway mucins in cystic fibrosis. Infect Immun. 2011 Aug;79(8):3438-44. doi: 10.1128/IAI.01252-10. Epub 2011 Jun 6.</citation>
    <PMID>21646446</PMID>
  </reference>
  <reference>
    <citation>Henke MO, John G, Germann M, Lindemann H, Rubin BK. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am J Respir Crit Care Med. 2007 Apr 15;175(8):816-21. Epub 2007 Jan 25.</citation>
    <PMID>17255563</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung</keyword>
  <keyword>airway</keyword>
  <keyword>pulmonary exacerbation</keyword>
  <keyword>mucus</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

